List view / Grid view
For decades, near-infrared (NIR) spectroscopy has been an invaluable tool within the laboratory and, interestingly, despite all the excellent instrumentation and technologies introduced for process control, NIR is still the most popular and mature technique available. This article will discuss the impact of NIR in pharmaceuticals from the perspective of…
Strong regimentation and economic interests demand the development and implementation of new techniques for process control and analysis in the pharmaceutical industry. The extensive analysis of all deployed materials, intermediates and products leads to a higher degree of process stability and can contribute to a faster compensation for deviations, especially…
Child safety, and specifically protection from poisoning, is a crucial factor in medicine packaging. In this article, Stephen Wilkins, Chairman of the Child-Safe Packaging Group, discusses the standards that govern child-safe packaging, as well as the importance of ‘ease of opening’ for elderly adults...
NIR technology has been used in the pharmaceutical industry for nearly two decades, but the major driver for its use over the last 10 years was recommendations made by the FDA and other regulating authorities.
In this issue: identification of peptides and proteins in suspected illegal medicinal products using MALDI-TOF-MS, and open data policies in proteomics.
Matrix-assisted laser desorption/ionisation (MALDI) time-of-flight (TOF) mass spectrometry (MS) has proven to be an excellent technique for identification of illegally distributed peptides and proteins for human use. The identification of proteins is mainly based on peptide mass fingerprinting (PMF) – ie, the bottom-up approach – while the small proteins and…
This near-infrared spectroscopy In-Depth Focus looks at online drying process control of pharmaceutical intermediates and how NIR has moved on from the lab.
In this edition of our 'Guide to' series we look at analytical testing instruments from SUEZ.
In this issue we look at the challenges of shipping temperature-controlled products, the potential use of blockchain for pharma, and using MALDI-TOF for identification of peptides in suspected illegal medicinal products. The edition also includes articles on aseptic containment, legal advice on licensing negotiations and an In-Depth Focus article from…
Consumer demands, a focus on sustainability and recycling, and political uncertainty in the UK are just a few challenges the packaging market had to overcome last year. Nikki Withers speaks to Ron Yakubison, Director of Pharmaceutical Packaging Operations at Merck Manufacturing and Sriman Banerjee, Head of Packaging at GSK, who…
As part of EPR’s Women in Pharma series, Dr Penny Heaton, Chief Executive Officer, Bill & Melinda Gates Medical Research Institute, talks to Science Editor Dr Zara Kassam about the need to disrupt global health product development by applying cutting-edge science and technology to combat age-old diseases in the world’s…
Rapid microbiological methods (RMM) continue to gain acceptance within our industry and a number of companies have already realised significant gains in detection sensitivity, automation, throughput, time-to-result and return on investment (ROI) when they have replaced their classical methods with these alternative technologies.
As part of EPR’s Women in Pharma series, Nawal Ouzren, CEO of Sensorion, talks to Science Editor Dr Zara Kassam about the diversity in drug development, creating a new growth mindset and elevating conversations beyond obvious beliefs...
Scale-up of pharmaceutical freeze-drying processes is cost and time consuming due to Quality by Design (QbD) requirements and novel compound costs or availability. The application of placebo formulations offers a promising way to improve drug development activities and save resources. Furthermore, placebos are used as a reference in clinical trials.…
As part of EPR’s Women in Pharma series, Ruth March, VP and Head of Precision Medicine and Genomics at AstraZeneca, talks to Science Editor Dr Zara Kassam about decreasing the clinical risk associated with solid tumour biopsy, balancing a scientific career with family life and taking advantage of company initiatives…
